|Grant, 10/07 |
National Institute of Standards and Technology
Origen Therapeutics, Inc., a biotechnology company, develops products from avian transgenic animal technology. It provides human sequence polyclonal antibodies. The company also develops a technology platform based on the genetic engineering of chicken embryonic cells, which can be genetically modified in such a way that the introduced genes are stably expressed in adult birds. Origen Therapeutics, Inc. was incorporated in 1997 and is based in Burlingame, California.